ID

23053

Description

https://clinicaltrials.gov/ct2/show/NCT01143272 Antibiotic-associated diarrhoea (AAD) is a frequent condition in hospitalised patients receiving antibiotic treatment. The same is true for Clostridium difficile-associated diarrhoea (CDAD) with even more grave consequences of increased morbidity and mortality. The development and evaluation of preventive strategies is one key public health challenge. In the absence of clinically evaluated alternatives, probiotics have been suggested to be beneficial for the prevention of AAD and CDAD. However, data have so far been inconclusive and recently published meta-analyses strongly recommended large state-of-the-art clinical trials on probiotic substances for the prevention of AAD and CDAD. Since the efficacy, side-effects and modes of action of different probiotic bacteria and yeast are strain specific, benefits and risks cannot be generalised. The non-pathogenic yeast Saccharomyces cerevisiae var. boulardii (Sac. boulardii) is considered the most promising probiotic substance for the prevention of AAD and CDAD. We carry out a randomised, placebo controlled, double blind multicentre clinical trial to evaluate Sac. boulardii for the indication of prevention of AAD and CDAD in 1520 adult, hospitalised patients.

Lien

https://clinicaltrials.gov/ct2/show/NCT01143272

Mots-clés

Versions (4)

1. 04/02/2016 04/02/2016 -
2. 11/02/2016 11/02/2016 -
3. 11/02/2016 11/02/2016 -
4. 21/06/2017 21/06/2017 - Martin Dugas

Téléchargé le

21 juin 2017

DOI

Pour une demande vous connecter.

Licence